Colonic polyp Medical Services in China

Colonic polyps are abnormal growths of tissue projecting from the mucosal lining of the large intestine (colon or rectum). They vary in size, morphology (e.g., pedunculated, sessile, flat), and histology—common types include adenomatous (precancerous), hyperplastic (typically benign), serrated (with variable malignant potential), and inflammatory polyps. Pathogenesis involves cumulative genetic and epigenetic alterations disrupting normal epithelial cell turnover; key drivers include APC gene mutations (initiating adenoma formation), KRAS and BRAF mutations, microsatellite instability, and aberrant Wnt signaling. Most sporadic polyps arise from age-related somatic mutations, while hereditary syndromes—such as familial adenomatous polyposis (FAP) and Lynch syndrome—confer markedly elevated lifetime risk due to germline defects in DNA mismatch repair or tumor suppressor genes. Epidemiologically, colonic polyps are highly prevalent: approximately 25–40% of adults aged 50–75 years harbor at least one polyp in screening colonoscopies in high-income countries; prevalence rises steadily with age, peaking after 65. In China, population-based studies report detection rates of 15–30% among asymptomatic adults over 50 undergoing colonoscopy, with increasing incidence linked to urbanization, Westernized diets, and aging demographics. Established risk factors include age ≥50 years, male sex, family history of colorectal cancer or advanced polyps, personal history of inflammatory bowel disease (especially ulcerative colitis >8–10 years), obesity, smoking, heavy alcohol use, sedentary lifestyle, and diets high in red/processed meats and low in fiber, calcium, and vitamin D. While most small polyps are asymptomatic, larger or proximal lesions may cause occult bleeding (leading to iron-deficiency anemia), visible rectal bleeding, changes in bowel habits (e.g., persistent constipation or diarrhea), mucus discharge, or, rarely, abdominal pain or obstruction. Importantly, quality of life impact extends beyond physical symptoms: patients often experience significant anxiety related to cancer risk, surveillance burden (repeated colonoscopies every 1–10 years depending on findings), procedural discomfort, time off work, travel for care, and out-of-pocket expenses—even when polyps are benign. Psychological distress is particularly pronounced in individuals with multiple polyps, high-risk histology (e.g., villous adenoma, high-grade dysplasia), or hereditary syndromes requiring lifelong multidisciplinary management. Early detection and removal during colonoscopy remain the cornerstone of prevention, reducing colorectal cancer incidence by up to 76–90% in compliant populations. Thus, colonic polyps represent not merely a pathological finding but a critical clinical opportunity for cancer interception and personalized risk stratification.

Colonic polyps are mucosal protrusions arising from the large intestinal wall, commonly detected during screening colonoscopy. While most are benign, certain histologic subtypes—including adenomas (tubular, villous, tubulovillous), serrated lesions (sessile serrated adenomas/polyps and traditional serrated adenomas), and rare neoplasms—carry variable malignant potential. Management is stratified by polyp size, morphology, number, histopathology, and patient-specific risk factors (e.g., family history of colorectal cancer, Lynch syndrome, or inflammatory bowel disease). Treatment in gastroenterology focuses on complete removal to prevent progression to colorectal cancer—the third most common malignancy worldwide.

Conservative treatment is reserved exclusively for select non-neoplastic polyps with negligible malignant risk. Hyperplastic polyps <5 mm located distal to the splenic flexure typically require no intervention beyond surveillance per guidelines (e.g., USMSTF, ESGE, or CSCO). Similarly, inflammatory pseudopolyps in quiescent ulcerative colitis or Crohn’s colitis do not mandate resection but necessitate ongoing endoscopic monitoring of underlying mucosal inflammation. Conservative management emphasizes rigorous adherence to evidence-based surveillance intervals: average-risk individuals with 1–2 small (<10 mm) tubular adenomas undergo repeat colonoscopy in 7–10 years; those with ≥3 adenomas, advanced histology (villous features, high-grade dysplasia, or size ≥10 mm), or sessile serrated polyps ≥10 mm require repeat examination in 3 years. Lifestyle modification—including smoking cessation, limiting red/processed meat intake, maintaining BMI <25 kg/m², and regular physical activity—is strongly recommended as adjunctive prevention, supported by cohort data linking these factors to reduced polyp recurrence.

Pharmacologic therapy plays a supportive, not primary, role. Aspirin (81–325 mg/day) demonstrates modest chemopreventive efficacy in patients with prior adenomas, particularly those with cardiovascular risk, though benefits must be weighed against gastrointestinal bleeding risk. Celecoxib (400 mg twice daily) is FDA-approved for familial adenomatous polyposis (FAP) as adjunctive therapy to delay colectomy; however, its long-term use is limited by cardiovascular toxicity concerns. Calcium supplementation (1,200 mg elemental calcium daily) and vitamin D (800–1,000 IU/day) show inconsistent but biologically plausible reductions in adenoma recurrence in meta-analyses. Statins and metformin are under investigation but lack definitive clinical trial validation for routine polyp prevention. No pharmacologic agent replaces endoscopic resection for existing neoplastic polyps.

Surgical treatment is indicated when endoscopic removal is unsafe, incomplete, or technically unfeasible. Endoscopic mucosal resection (EMR) is first-line for non-pedunculated polyps ≤20 mm and pedunculated polyps with stalk diameter <5 mm. For larger lesions (≥20 mm), especially those with complex morphology (e.g., lateral spreading tumors), endoscopic submucosal dissection (ESD) offers superior en bloc resection rates (>90%) and lower local recurrence (<5%) compared to piecemeal EMR. In China, ESD has been widely adopted since 2010, with standardized training programs across tertiary centers. Surgical colectomy remains necessary for invasive carcinoma within a polyp with deep submucosal invasion (>1,000 µm), lymphovascular invasion, poorly differentiated histology, or positive margins after endoscopic resection. Patients with FAP, attenuated FAP, or hereditary nonpolyposis colorectal cancer (Lynch syndrome) may require prophylactic total colectomy or proctocolectomy based on cumulative polyp burden and genetic counseling.

Treatment advantages in China include unparalleled endoscopic expertise, rapid technological integration, and cost-effective care delivery. Over 95% of Class III-A hospitals (China’s highest-tier institutions) perform high-volume ESD with complication rates (perforation <2%, delayed bleeding <3%) comparable to Japanese and Korean benchmarks. Real-time AI-assisted polyp detection systems (e.g., EndoAngel®) deployed in >200 hospitals improve adenoma detection rates by 12–18%, reducing post-colonoscopy colorectal cancer incidence. National polyp registry initiatives enable longitudinal outcome tracking, while standardized pathology reporting (aligned with WHO 5th edition criteria) ensures diagnostic consistency. Furthermore, China’s tiered healthcare system facilitates seamless referral from community clinics to specialized endoscopy centers, and government-subsidized colonoscopy programs have expanded screening access—particularly in urban centers—contributing to earlier-stage detection and improved 5-year survival (>90% for stage I colorectal cancer).

Post-procedure recovery requires structured guidance. Patients undergoing EMR or ESD should observe strict dietary progression: clear liquids for 24 hours, followed by low-residue soft foods for 3–5 days, then gradual reintroduction of fiber over 1–2 weeks. Anticoagulants (e.g., warfarin, DOACs) and NSAIDs must be withheld per protocol—typically 5–7 days pre- and 7–14 days post-procedure—based on bleeding risk assessment. Vigilance for alarm symptoms (hematochezia >100 mL, persistent tachycardia, fever >38.5°C, or severe abdominal pain) warrants urgent evaluation. Follow-up colonoscopy timing is dictated by histopathology and quality of resection: optimal surveillance intervals are calculated using validated tools such as the ASGE Post-Polypectomy Surveillance Guidelines. Long-term adherence to surveillance is critical—studies indicate that only 65–75% of Chinese patients comply with recommended follow-up, underscoring the need for integrated electronic health record reminders and nurse-led education. Finally, patients should undergo genetic counseling if histology reveals mismatch repair deficiency (dMMR), BRAF V600E mutation, or multiple synchronous advanced lesions—facilitating cascade testing for hereditary syndromes. Comprehensive, multidisciplinary care—integrating gastroenterology, pathology, genetics, and nutrition—remains the cornerstone of effective colonic polyp management.